GlaxoSmithKline plc’s Dividends Set To Reach 5.4%!

The City is forecasting a return to earnings growth for GlaxoSmithKline plc (LON: GSK), too.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The latest big news for GlaxoSmithKline (LSE: GSK) (NYSE: GSK) is its new deal with Novartis — some assets will be transferred in one direction, others in the opposite direction, and there will be a new joint venture to deal with a lot of the two companies’ consumer products.

It seems like a good idea for each company to focus on what it does best, though it will take some time for that to feed through to the bottom line.

Strong outlook

But for GlaxoSmithKline at least, any benefits will add to what is already looking like a decent outlook for the company over the next couple of years.

GlaxoSmithKlineThrough its vast product diversification and a big financial commitment to its drugs-development pipeline, Glaxo has been coping with the effects of the patent cliff pretty well — some blockbusters have lost patent protection and there is increasing competition from generic alternatives.

And while some may have expected a few years of falling earnings, as currently experienced by rival AstraZeneca, Glaxo has managed to keep its earnings stable — analysts are expecting just a 2% fall in earnings per share (EPS) for the year to December 2014. And while the AstraZenenca dividend was frozen, Glaxo’s has kept on growing.

Return to growth

For 2015, there’s a return to growth with a 9% EPS rise on the cards — and that all-important dividend is set to rise again, from an expected yield of 5.2% this year to 5.4% on today’s 1,650p price level.

gskThe trend in the analysts’ consensus, however, has been downwards — as it has been with a lot of the FTSE’s top shares over the past 12 months. A year ago, we were looking at a consensus for 2014 earnings of 125p per share, though that has steadily falling and the City boys are now expecting 110p. It’s a disappointing drop, but it does still leave the shares on a forward P/E of 15, and that’s lower than the current average.

Forecasts for 2015 have fallen in line, with a mooted EPS figure of 131p three months ago being downgraded to 119p today — but that drops the P/E to 14, which is attractive.

The trend in dividend forecasts has been more encouraging, with the 2014 forecast having been dropped by only a penny from the 81.8p the analysts were predicting a year ago to 80.8p today. It won’t be very well covered by earnings, but it should be safe enough.

Cautious for now

With such a cautious trend, it’s perhaps not surprising to see the bulk of around 30 analysts sticking to a Hold recommendation at the moment — but that could change when they’ve had time to scratch their heads over the Novartis tie-up.

The next few months should be interesting for Glaxo watchers.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan does not own any shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Mixed-race female couple enjoying themselves on a walk
Investing Articles

Are Raspberry Pi shares a once-in-a-lifetime chance to get rich?

With Raspberry Pi shares surging after a successful IPO, could this UK tech startup offer a long-term wealth creation opportunity…

Read more »

Newspaper and direction sign with investment options
Investing Articles

Huge gains and 9% yields: why now’s an amazing time to be a stock market investor

The stock market’s generating fantastic returns in 2024. Whether you're looking for gains or income, it’s a great time to…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

This steady dividend payer looks like one of the best bargain stocks in the FTSE 100

A yield of 4.7% and a consistent dividend record make this FTSE 100 company look like good value in an…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

£9,000 in savings? That could become passive income of £19,175 a year

It's possible to invest affordable sums of money into building a big passive income stream. Here's how I'd go about…

Read more »

Black father and two young daughters dancing at home
Investing Articles

Legal & General shares: a once-in-a-decade passive income opportunity?

Is a dividend yield at its highest level in a decade, combined with a strong record of increasing payouts, a…

Read more »

Investing Articles

With a 7% yield and 4.1 P/E, is this the best passive income stock on the FTSE 350?

Millions of Britons invest for a passive income. While our writer isn't buying this stock yet, he believes it's worth…

Read more »

Middle-aged Caucasian woman deep in thought while looking out of the window
Investing Articles

This amazing FTSE 250 has a 8.8% dividend yield and trades at just 4x forward earnings!

Our Foolish writer believes this FTSE 250 stock is worth keeping a very close eye on. However, he's not keen…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Could this brilliant airline stock be the most undervalued company on the FTSE 100?

Our writer believes this FTSE 100 stock may provide market-beating returns over the coming years, noting its undervalued metrics and…

Read more »